Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Voorhees, Peter M. , Martin, Tom, Lin, Yi , Htut, Myo , Deol, Abhinav , Dhakal, Binod , de, Rocío Montes , Sun, Huabin, Lendvai, Nikoletta , Koneru, Mythili, Patel, Nitin , Cohen, Adam D. , Raje, Noopur , Agha, Mounzer , Berdeja, Jesús G. , Dhakal, Binod , Jakubowiak, Andrzej , Parekh, Samir , Li, Hui, Madduri, Deepu , Jagannath, Sundar

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 7507-7507

10.1200/jco.2025.43.16_suppl.7507 Get It

7507 Background: CARTITUDE-1 evaluated cilta-cel in pts with heavily pretreated RRMM who historically have an expected median progression-free survival (PFS) of <6 months (mo) and median overall survival (OS) of ~1 year (y). At 33.4 mo median follow-up, median PFS was 34.9 mo, and median OS was not reached (36-mo OS rate, 62.9%; Lin et al, ASCO 2023). We report OS, ≥5 y progression-free outcomes, and safety with a median study follow-up of 60.3 mo. Methods: Pts in CARTITUDE-1 received a single cilta-cel infusion. Correlative analyses were performed utilizing drug product, baseline, and postinfusion samples. Pts are followed for progression, survival, and safety in a 15-y follow-up study, CARTinue (NCT05201781), with pt evaluations per local standard of care (reported annually at a minimum). Results: Of 97 pts treated, 32 (33.0%) remain alive and progression free for ≥5 y after cilta-cel, without further MM treatment. For these 32 pts, prior to enrollment in CARTITUDE-1, median time from start of last line of therapy (LOT) to progression was 4.0 mo (range, 0.7–48.6). Among the 32, median age was 60 y (range, 43–78), median number of prior LOT was 6.5 (range, 3–14), 23.3% had high risk cytogenetics, 12.5% had extramedullary disease (EMD), 90.6% were triple-class refractory, and 46.9% were penta-drug refractory. Baseline characteristics of pts who were progression free for ≥5 y, including those with high-risk cytogenetics and EMD, were comparable to pts with progressive disease (PD) within 5 y. Compared with pts who had PD within 5 y, biomarkers significantly associated with ≥5 y progression free status included a higher fraction of naïve T cells in the drug product, lower neutrophil to T cell ratio, higher hemoglobin and platelets at baseline, and higher effector-to-target ratio (Cmax to sBCMA at baseline). At Cmax, these pts also had significantly higher CD4 central memory CAR+ T cell subsets and CAR+ T cells that were positive for the activation markers CD38, CD25, and PD-1. Data were collected on a subset of pts from a single center where local serial MRD assessments were performed. All 12 pts at this center who were progression free for ≥5 y were MRD negative at 10 –6 and imaging negative by PET/CT yearly for 5 y. Overall, at 60.3 mo median follow-up in CARTITUDE-1 (N=97), median OS was 60.6 mo (95% CI, 41.9–NE). With continued follow-up, 3 additional pts reported a second primary malignancy (1 of which was acute myeloid leukemia; onset, 2.8 y after infusion). No new cases of movement and neurocognitive disorders were reported. Conclusions: The median OS for pts enrolled in CARTITUDE-1 was 5 y, and 33% of pts remain progression free for ≥5 y following a single cilta-cel infusion. These data provide the first evidence that cilta-cel is potentially curative in pts with RRMM. Clinical trial information: NCT03548207 , NCT05201781 .
Clinical and radiometabolic correlatives of ddPCR liquid biopsy for BRAF V600 mutated melanoma.
Block, Matthew S. , Kipp, Benjamin R. , Nikanpour, Yalda , Bilgin, Gokce Belge , Markovic, Svetomir, Stoff, Ronen , Johnson, Geoffrey B.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e15046 Get It

e15046 Background: BRAF V600 is the most common driver mutation in melanoma, seen in ≈50% of patients. Recently, the use of liquid biopsy assays that are based on circulating tumor DNA (ctDNA) has become widespread for diagnosis and residual disease monitoring. We have previously reported on our droplet digital PCR (ddPCR) test as a liquid biopsy for BRAF mutant (BRAFm) melanoma. Here we report the correlation between clinical and radiological parameters and ddPCR test results. Methods: Using the department of laboratory medicine archives, we have identified all biopsy proven BRAFm melanoma patients that were tested with the BRAF V600 ddPCR assay at our institution over the years 2018-2024. All patients had blood samples collected, and cell free DNA (cfDNA) was extracted from plasma using the Qiagen QIAamp Circulating Nucleic Acid Kit. cfDNA was evaluated with a BioRad QX200 droplet digital PCR platform assessing for BRAF V600E/K mutations. Clinical and demographic data were collected from medical records. Radiometabolic features including volumetric data and FDG PET SUV values were collected and analyzed using the MIM software (MIM Software Inc., Beachwood, OH, USA). Univariate and multivariate analyses were used to assess correlations between baseline variables and test results. Results: 71 patients were identified. The median age was 59 (26-85), 54% were males. 46 patients (65%) had a positive test result which was based on a cut-off of ≥4 mutant copies per ml. 65 patients (92%) had active disease on imaging studies, of which those with a positive test result were younger (p = 0.047), had a higher proportion of osseous metastases (p = 0.02) and had a higher number of lesions (p = 0.006). There was no difference in the median overall survival between the groups (11 months vs. 33 months for positive and negative result respectively, log-rank test; p = 0.15). Total tumor volume on PET-CT (in ml) was predictive of the quantitative ddPCR test result (in copies per ml), with every increase in 10 ml of tumor leading to an expected increase of 370 copies per ml (p < 0.001). Multivariate models have failed to show a correlation between baseline parameters and the quantitative ddPCR test result. When performing the analyses using logistic regression models with the binary ddPCR test result as the outcome, osseous metastases were predictive in a univariate model (OR = 4.3, 95% CI 1.4-15.4). The best fit multivariate model showed that higher burden of disease with ≥6 lesions (OR = 6.57, 95% CI 1.24-44.3) and elevated LDH (OR = 8.8, 95% CI 1.83-56.91) were associated with an increased risk for a positive result, while younger age was associated with decreased risk for a positive result (OR = 0.92, 95% CI 0.86-0.97). Conclusions: The results of ddPCR testing for BRAF mutation are correlated with the radiological and volumetric extent of the disease. This test could be useful in patients presenting with high-burden disease when a fast turnaround time is needed.
NeoACTIVATE arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable stage III melanoma.
Zahrieh, David , Flotte, Thomas J. , Dronca, Roxana , Nelson, Garth D. , Kottschade, Lisa A. , Montane, Heather N. , Chen, Ruqin , Jakub, James W., Tasche, Kendall K. , Block, Matthew S. , Hieken, Tina J. , Domingo‐Musibay, Evidio , Strand, Carrie , Piltin, Mara A. , McWilliams, Robert R. , Khariwala, Samir S , Dudek, Arkadiusz Z. , Johnson, Jeffrey , Markovic, Svetomir N. , Dimou, Anastasios

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 9503-9503

10.1200/jco.2025.43.16_suppl.9503 Get It

9503 Background: Neoadjuvant ± adjuvant immunotherapy improves event-free survival relative to adjuvant immunotherapy alone for patients with high-risk resectable stage III melanoma. However, the optimal regimen balancing efficacy and tolerability is not known. T-cell immunoglobulin and ITIM domain (TIGIT) is a promising immune checkpoint but its therapeutic potential in stage III melanoma is underexplored. Methods: In this phase II trial, patients with resectable, macroscopic stage III melanoma received four 21-day neoadjuvant cycles of 1200mg IV atezolizumab (atezo, anti-PD-L1) + 600mg IV tiragolumab (tira, anti-TIGIT), followed by therapeutic lymph node dissection (TLND) and eight 21-day adjuvant cycles of 1200mg IV atezo. Primary endpoints were pathologic response (of all patients initiating neoadjuvant therapy) and recurrence-free survival (RFS) from the time of TLND in patients who were operated on per protocol and received adjuvant therapy. Secondary endpoint was adverse events (AEs); exploratory endpoints included event-free survival (EFS) and distant metastasis-free survival (DMFS). Results: Thirty-four patients, median age 59 years, were accrued and initiated neoadjuvant atezo/tira. 76.5% had >1 metastatic lymph node involved at baseline and 73.5% presented with Stage IIIC disease. All 34 patients were evaluable for AEs, pathologic response and EFS. Four patients were diagnosed with metastatic disease during neoadjuvant treatment, while 30 had TLND per protocol and 28 received adjuvant treatment and were evaluable for RFS and DMFS. Major pathologic responses (MPR, ≤10% viable tumor) were observed in 16/34 patients (47.1%, Table). With 19.9 months median follow-up from registration, 12-month EFS was 72.0% (95% CI 57.9 to 89.5%). With 16 months median follow-up from operation, 12-month RFS was 73.3% (n=28, 95% CI 56.9 to 94.5%), while 12-month DMFS was 86.0% (n=28, 95% CI 72.2 to 100%). In the 16 patients with an MPR, 2 did not receive adjuvant treatment and were followed for 33.3 and 10.8 months without recurrence/death. In the remaining 14 patients, 12-month RFS and 12-month DMFS were both 91.7% (95% CI 77.3 to 100%). 5 patients (14.7%) experienced any grade 3+ AE with 2 (5.9%) at least possibly related to the neoadjuvant regimen. Conclusions: Among patients with high-risk resectable stage III melanoma, neoadjuvant atezo/tira was a promising regimen with a favorable safety profile and warrants further study. Identification of predictive biomarkers will allow for optimization of neoadjuvant therapy for individual patients. Clinical trial information: NCT03554083 . Pathologic response. N=34 Major Pathologic Response 16 (47.1%) Pathologic complete response (no viable tumor) 13 (38.2%) Near-pathologic complete response (0.1−10% viable tumor) 3 (8.8%) Pathologic partial response (>10.0−50% viable tumor) 2 (5.9%) Pathologic non-response (>50% viable tumor) 12 (35.3%) No per protocol operation 4 (11.8%)
BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): Clinical update and first report of pharmacokinetics (PK) and
Arbour, Kathryn C. , George, Ben , Henry, Jason T. , Leventakos, Konstantinos , Ahnert, Jordi Rodon, Papadopoulos, Kyriakos P. , Perez, Cesar A. , Zuniga, Richard, Wozniak, A., Chin, Curtis D., Mazzei, Antonella , Hu, Zheyi , Simpson, Tyler R., Dickinson, Adam , Jänne, Pasi A. , Ahnert, Jordi Rodon, Johnson, Melissa L. , Spira, Alexander I. , Babiker, Hani M. , Haddox, Candace L. , Chin, Curtis

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3011-3011

10.1200/jco.2025.43.16_suppl.3011 Get It

3011 Background: BMS-986504 selectively binds to the PRMT5-MTA complex, which represents a synthetic lethal target in MTAP -del cancer cells, while sparing MTAP– wild-type cells. In the first-in-human phase 1/2 CA240-0007 study in advanced, unresectable or metastatic solid tumors with homozygous MTAP -del, BMS-986504 was found to be well tolerated and demonstrated antitumor activity in multiple tumors. Here, we report clinical results and the first PK and PD analyses of BMS-986504 from the dose escalation and expansion phases of CA240-0007. Methods: Pts with measurable/evaluable disease and no available treatment (Tx) with curative intent were enrolled; 7 doses were evaluated (50 to 800 mg) in dose escalation. Objective response rate (ORR), disease control rate (DCR), duration of response (DOR), time to response (TTR), safety, PK, PD, including plasma SDMA were assessed. Results: As of 2 Dec 24, 152 heavily pretreated pts were enrolled across all doses: NSCLC (n = 34), PDAC (n = 41), cholangiocarcinoma (n = 12), and mesothelioma (n = 12) were the most common tumor types. With a median f/u of 9.0 mo (95% CI 7.6–9.9), continued durable antitumor activity and deepening tumor regression were seen across tumor types and doses (ORR = 23%, DCR = 70%, median DOR = 10.5 mo, TTR = 4.6 mo). No new safety signals were identified. Most Tx-related adverse events (TRAEs) were grade (Gr) 1 or 2; 13% had Gr ≥ 3 TRAEs (Gr 3 = 12%, Gr 4 = < 1%, Gr 5 = 0). Doses from 50 to 600 mg QD were assessed for PK/PD. The AUC (0-24) after multiple doses was approximately dose proportional at 200 to 600 mg, and the terminal t 1/2 after a single dose was approximately 24 h (table). There were dose-dependent reductions in predicted plasma SDMA, with the 400 and 600 mg doses approaching the plateau. Conclusions: With longer f/u, BMS-986504 continued to show increasingly durable antitumor activity. BMS-986504 demonstrated a favorable PK/PD profile, supporting QD dosing at 400 and 600 mg. These results support further investigation of BMS-986504 at 400 and 600 mg QD as a potential first-in-class synthetic lethal Tx option in pts with advanced solid tumors with MTAP -del. Clinical trial information: NCT05245500 . PK and PD. 50 mg QD 100 mg QD 200 mg QD 400 mg QD 600 mg QD PK after multiple doses t max a (min–max), h 2.0 (2.0–4.0)n = 3 2.0 (1.0–2.0)n = 3 2.0 (0.5–6.0)n = 8 2.0 (0.5–4.0)n = 10 2.0 (1.0–6.0)n = 10 C max , b ng/mL 107n = 3 377n = 3 685n = 8 1240n = 10 2110n = 10 AUC (0-24) , b h∙ng/mL 948 n = 3 3060 n = 3 7150 n = 7 11,800n = 10 26,700n = 9 AUC (0-24) , b,c h∙ng/mL/mg 19.0n = 3 30.6n = 3 35.8n = 7 29.5n = 10 44.6n = 9 Terminal t 1/2 after single dose, d h 21.7 n = 1 80.7 n = 1 21.5 n = 14 21.7 n = 14 24.1 n = 1 PD Translational exposure targets (C avgss ), X 0.08 0.21 0.5 1.1 1.7 Predicted plasma SDMA reduction, a % (90% PI) 30.0 (23.2–37.8) 38.8 (27.1–47.5) 48.3 (42.0–53.0) 55.0 (50.7–57.6) 57.4 (54.3–59.0) a Median. b Geometric mean. c Dose-normalized. d Arithmetic mean.
Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial.
Aizer, Ayal A. , Benham, Grant, Brown, Paul D. , Cagney, Daniel , Catalano, Paul J. , Chipidza, Fallon , Haas‐Kogan, Daphne A. , Hepel, Jaroslaw T., Krishnan, Monica, Johnson, Marciana, Lamba, Nayan , Nosker, Jennifer , Parsons, Michael , Peng, Luke , Ricca, Ivy, Wen, Patrick Y. , Rahman, Rifaquat , Parsons, Michael W , Tanguturi, Shyam K , Shi, Diana D. , Shin, Kee‐Young , Wen, Patrick Yung

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 2011-2011

10.1200/jco.2025.43.16_suppl.2011 Get It

2011 Background: Radiation therapy forms the mainstay of management for patients with brain metastases. Published randomized trials have found improved quality of life with stereotactic radiation (SRS/SRT) over whole brain radiation (WBRT) in patients with ≤ 4 brain metastases; comparative trials in patients with >4 brain metastases are lacking. In addition, prior randomized trials have demonstrated the superiority of hippocampal avoidance WBRT (HA-WBRT) over traditional WBRT, but no study has compared SRS/SRT to HA-WBRT. Accordingly, we conducted a multicenter, phase 3 randomized trial comparing SRS/SRT to HA-WBRT in patients with 5-20 brain metastases. Methods: Eligible patients were age 18-80 with 5-20 brain metastases secondary to a solid primary other than small cell lung cancer, were naïve to prior brain-directed radiation, and lacked leptomeningeal disease. The primary endpoint was the average of patient-reported symptom severity and interference over the first six months post-baseline relative to baseline, using the MD Anderson Symptom Inventory–Brain Tumor (MDASI-BT) module, a validated instrument assessing 22 symptoms and 6 interference measures integral to quality of life, each scored 0-10 with higher scores indicating greater symptomatology/interference in function. The target effect size was a symptom severity of 0.70, corresponding to 50% of the observed difference between patients with a good (90-100) versus poor (≤80) Karnofsky performance status; with 80% power and a two-sided alpha of 0.05, 196 patients were required. Results: Between 4/2017-5/2024, 196 patients enrolled, 98 in each arm. The median number of brain metastases was 14 (IQR 11-18); 25% of patients underwent prior neurosurgical resection. Baseline mean MDASI-BT symptom severity scores were 2.2 (SRS/SRT arm) and 1.9 (HA-WBRT arm), p=0.20; respective interference scores were 3.5 and 3.2 (p=0.40). The average of weighted post-baseline severity and interference scores relative to baseline indicated lower symptomatology/inference in the SRS/SRT arm, meeting the primary endpoint of the study (difference between SRS/SRT and HA-WBRT: -1.06, p<0.001). Averaged post-baseline symptom severity scores minus baseline were -0.03 and 0.59 in the SRS/SRT and HA-WBRT arms, respectively (difference -0.62, with lower symptom severity in the SRS/SRT arm, p<0.001); respective interference estimates were -0.62 and 0.89 (difference -1.50, with lower interference in the SRS/SRT arm, p<0.001). Median survival was 8.3 and 8.5 months in the SRS/SRT and HA-WBRT arms, respectively (p=0.30). Conclusions: This phase 3 randomized trial indicates that patients with 5-20 brain metastases experience fewer symptoms and less interference in function after SRS/SRT as opposed to HA-WBRT, without compromise of survival, supporting SRS/SRT as the standard of care in this population. Clinical trial information: NCT03075072 .
Deep learning on brief interictal intracranial recordings can accurately characterize seizure onset zones
Sundrani, Sameer , Doss, Derek J. , Makhoul, Ghassan S. , Lerma, Bruno Hidalgo Monroy , Reda, Anas, Cavender, Addison C. , Liao, Emily, Bick, Sarah K. , Morgan, Victoria L. , Englot, Dario J. , Doss, Derek J , Hidalgo Monroy Lerma, Bruno , Morgan, Victoria L , Englot, Dario J , Bick, Sarah K , Johnson, Graham W. , Rogers, Baxter P. , Williams Roberson, Shawniqua

Mayo Clinic

Epilepsia | May 27, 2025 | Volume: 66 | Issue: 9 | Pages: 3180-3192

10.1111/epi.18478 | PMID 40423629 Get It

AbstractObjectiveEpilepsy is a debilitating disorder affecting more than 50 million people worldwide, and one third of patients continue to have seizures despite maximal medical management. If patients' seizures localize to a discrete brain region, termed a seizure onset zone, resection may be curative. Localization is often confirmed with stereotactic electroencephalography; however, this may require patients to stay in the hospital for weeks to capture spontaneous seizures. Automated localization of seizure onset zones could therefore improve presurgical evaluation and decrease morbidity.MethodsUsing more than 1 000 000 interictal stereotactic electroencephalography segments collected from 78 patients, we performed five‐fold cross‐validation and testing on a multichannel, multiscale, one‐dimensional convolutional neural network to classify seizure onset zones.ResultsAcross held‐out test sets, our models achieved a seizure onset zone classification sensitivity of .702 (95% confidence interval [CI] = .549–.805), specificity of .741 (95% CI = .652–.835), and accuracy of .738 (95% CI = .687–.795), which was significantly better than models trained on random labels. The models performed well across the entire brain, with top five region performance demonstrating accuracies between 70.0% and 88.4%. When split by outcomes, the models performed significantly better on patients with favorable Engel outcomes after resection or who were responsive neurostimulation responders. Finally, SHAP (Shapley Additive Explanation) value analysis on median‐normalized input data assigned consistently high feature importance to interictal spikes and large deflections, whereas similar analyses on histogram‐equalized data revealed differences in feature importance assignments to low‐amplitude segments.SignificanceThis work serves as evidence that deep learning on brief interictal intracranial data can classify seizure onset zones across the brain. Furthermore, our findings corroborate current understandings of interictal epileptiform discharges and may help uncover novel interictal morphologies. Clinical application of our models may reduce dependence on recorded seizures for localization and shorten presurgical evaluation time for drug‐resistant epilepsy patients, reducing patient morbidity and hospital costs.
Characteristics of Daily Walking Bouts as Valid and Reliable Indicators of Exercise Capacity in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE)
Rehman, Rana Zia Ur , Parisi, Federico , Ashraf, Noman , Chatterjee, Meenakshi , Frantz, Robert P. , Hemnes, Anna R. , Manyakov, Nikolay V. , Yardibi, Tarik, Selej, Mona , Mansi, Tommaso , Dunnmon, Preston , Selej, Mona , Kaliukhovich, Dzmitry A , Frantz, Robert P , Hemnes, Anna , Carrasco‐Zevallos, Oscar M.

Mayo Clinic

Pulmonary Circulation | May 27, 2025 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/pul2.70097 | PMID 40433632 Get It

ABSTRACTThere is a need for objective, continuous and remote assessment of exercise capacity in patients with pulmonary arterial hypertension (PAH). Using data from the TRACE study, in which 108 adult patients with PAH were continuously monitored with a wrist‐worn accelerometer, we evaluated whether actigraphy can facilitate continuous monitoring of exercise capacity. Distributions of step rate, distance and duration of patient's walking bouts were estimated at baseline, Week 16 and Week 24 using 2‐week periods of actigraphy data. Twenty‐one metrics per walking bout characteristic were described (mean, standard deviation, 19 percentiles [5th–95th]). The relationships between these metrics and the 6‐min walk distance (6MWD), Borg dyspnea index (BDI), and the PAH Symptoms and Impact questionnaire (PAH‐SYMPACT) Physical Impact domain score were assessed at the three timepoints. Test‐retest reliability, and discriminant and known‐group validity of each metric were also evaluated. All metrics of step rate and bout distance were significantly correlated with 6MWD (Pearson's correlation coefficients: 0.34–0.67; p < 0.005) and the PAH‐SYMPACT Physical Impact domain score (Pearson's correlation coefficients: −0.51 to −0.32; p < 0.05) at all timepoints. Negative correlations were also observed with the BDI and the actigraphy‐derived metrics, with the majority reaching significance. Strong test‐retest reliability was demonstrated (intra‐class correlation coefficient ≥ 0.70). The metrics differentiated well between patients with varying disease severity levels. In conclusion, actigraphy‐derived metrics of patients' walking bouts correlate significantly with 6MWD, BDI and physical impacts of PAH, indicating the utility of actigraphy in facilitating continuous monitoring of exercise capacity in adult patients with PAH.Trial RegistrationClinicalTrials.gov: NCT03078907; URL: clinicaltrials.gov.
Improving Preparatory Materials for the Pediatric Infectious Diseases Initial Certifying Exam: A Targeted Needs Assessment
Sattler, Matthew M , Ristagno, Elizabeth H. , Boguniewicz, Juri , Fatemi, Yasaman , Jamal, Hassan H. , Vidal, Diego A Cruz , Boguniewicz, Juri , Jamal, Hassan, Parzen-Johnson, Simon

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | May 25, 2025 | Volume: 14 | Issue: 6 | Pages: No page available

10.1093/jpids/piaf048 | PMID 40413637 Get It

Abstract We conducted a national survey of current pediatric infectious diseases (PID) fellows and PID fellowship graduates from the past 10 years to assess satisfaction with existing PID initial certifying exam preparatory materials. Satisfaction with existing resources was low. The most desired new resource was additional board-style questions.
Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage
Collaborators, GBD 2021 Global Subarachnoid Hemorrhage Risk Factors, Rautalin, Ilari, Stark, Benjamin, Johnson, Catherine O., Kaprio, Jaakko , Korja, Miikka, Krishnamurthi, Rita , Nair, Balakrishnan , Vergouwen, Mervyn D. I. , Abdelkader, Atef , Abdullahi, Auwal , Abualruz, Hasan , Abukhadijah, Hana J , Adamu, Lawan Hassan, Adegboye, Oyelola A. , Adzigbli, Leticia Akua, Agyemang‐Duah, Williams , Ahinkorah, Bright Opoku, Ahmad, Aqeel , Ahmad, Danish , Ahmadzade, Amir Mahmoud , Akkaif, Mohammed Ahmed , Ali, Mohammed Usman, Alif, Sheikh Mohammad , Alimohamadi, Yousef, Alsabri, Mohammed , Altaf, Awais , Alvis‐Guzmán, Nelson , Alwafi, Hassan , Al‐Wardat, Mohammad , Alyahya, Mohammad S. , Amin, Tarek Tawfik , Amindarolzarbi, Alireza , Amusa, Ganiyu , Angappan, Dhanalakshmi , Anuoluwa, Boluwatife Stephen, Anwar, Saleha, Anyasodor, Anayochukwu Edward , Apostol, Geminn Louis Carace, Areda, Demelash, Artamonov, Anton A, Artanti, Kurnia Dwi , Ashemo, Mubarek Yesse , Athar, Mohammad , Aujayeb, Avinash , Awotidebe, Adedapo Wasiu , Azadnajafabad, Sina , Aziz, Shahkaar , Bagheri, Nasser , Taqanaki, Pegah Bahrami , Bahramian, Saeed , Bai, Ruhai , Baig, Atif Amin , Baltatu, Ovidiu Constantin , Bam, Kiran, Barker‐Collo, Suzanne , Bärnighausen, Till , Bastan, Mohammad‐Mahdi , Basu, Sanjay , Bell, Shelly L, Benseñor, Isabela M , Berhie, Alemshet Yirga , Bhagavathula, Akshaya Srikanth , Bhaskar, Sonu , Bhat, Ajay Nagesh, Bhat, Vivek , Birhan, Mekuriaw Mesfin , Borhany, Hamed, Breitner, Susanne , Bulamu, Norma B. , Butt, Zahid A , Cabral, Lucas Scotta , Santos, Florentino Luciano Caetano dos , Cámera, Luis Alberto , Capodici, Angelo , Chadwick, Joshua , Chakraborty, Promit Ananyo , Chanie, Gashaw Sisay , Chattu, Vijay Kumar , Chi, Gerald, Chichagi, Fatemeh , Columbus, Alyssa , Criqui, Michael H, Ohadi, Mohammad Amin Dabbagh , Dadras, Omid , Dalli, Lachlan L. , Debopadhaya, Shayom , Dervišević, Emina , Devanbu, Vinoth Gnana Chellaiyan, Dewan, Syed Masudur Rahman , Dhane, Amol S. , Chi, Thanh, Phuong, Thao Huynh, Dohare, Sushil , Докова, Клара , Dowou, Robert Kokou , Dsouza, Haneil Larson , Dutta, Siddhartha , Dziedzic, Arkadiusz , E’mar, Abdel Rahman, Edvardsson, David , Efendi, Ferry, Nahas, Nevine El , Elgendy, Islam Y. , Eltaha, Chadi, Emeto, Theophilus I. , Fakhradiyev, Ildar , Faris, Pawan , Fauk, Nelsensius Klau , Fazylov, Timur, Fekadu, Ginenus , Fetensa, Getahun, Fischer, Florian, Foschi, Matteo , Fridayani, Ni Kadek Yuni, Gaipov, Abduzhappar , Gajjar, Avi A. , Ganesan, Balasankar , Gebregergis, Miglas Welay, Gebremeskel, Teferi Gebru , Getie, Molla , Ghadirian, Fataneh , Ghasemzadeh, Afsaneh , Gholamalizadeh, Maryam , Gil, Artyom , Goleij, Pouya , Goulart, Alessandra C. , Goulart, Bárbara Niegia Garcia de , Guan, Shi‐Yang , Gupta, Sapna , Habibzadeh, Farrokh , Hadi, Najah R, Hankey, Graeme J. , Harlianto, Netanja I. , Hasani, Hamidreza, Hasnain, Md Saquib , Haubold, Johannes , Havmoeller, Rasmus, Hay, Simon I , Hbid, Youssef , Heidari, Golnaz , Hiraike, Yuta, Hoan, Nguyen Quoc , Hosseinzadeh, Mehdi , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ikiroma, Adalia , Isola, Gaetano , Iwagami, Masao , Jacob, Louis, Jain, Akhil, Jakovljević, Mihajlo , Jatau, Abubakar Ibrahim , Jawaid, Talha, Jayapal, Sathish Kumar , Jonas, Jost B, Joseph, Nitin , Jürisson, Mikk , Kadashetti, Vidya, Kalani, Rizwan, Kamireddy, Arun , Kandel, Himal , Behnagh, Arman Karimi , Kashoo, Faizan , Kayode, Gbenga A , Kazemi, Foad , Khader, Yousef , Khaing, Inn Kynn , Khan, Fayaz Ahmad , Khan, Mohammad Jobair , Kashani, Hamid Reza Khayat , Khosla, Atulya Aman , Kim, Kwanghyun , Kim, Yun Jin , Korzh, Oleksii , Krishan, Kewal , Krishna, Varun, Krishnamoorthy, Vijay , Kuddus, Mohammed , Kulimbet, Mukhtar , Lahariya, Chandrakant, Lai, Daphne Teck Ching , Lai, Hanpeng , Laksono, Tri, Lallukka, Tea , Latifinaibin, Kaveh, Le, Nhi Huu Hanh, Le, Thao T. , Lee, Munjae , Lee, Yo Han , Lenzi, Jacopo , Leonardi, Matilde, Li, Ming‐Chieh , Li, Xiaopan , Lim, Stephen S , Lin, Jialing , Saute, Ricardo Lutzky , Malik, Ahmad Azam , Marateb, Hamid Reza , Maroufi, Seyed Farzad , Maugeri, Andrea , McPhail, Steven , Mehndiratta, Man Mohan, Mestrovic, Tomislav, Mettananda, Chamila Dinushi Kukulege , Miazgowski, Tomasz , Minervini, Giuseppe , Mithra, Prasanna , Mohamed, Abdalla Z. , Mohammad, Ameen Mosa , Mohammed, Shafiu , Moni, Mohammad Ali , Moradi, Yousef, Moraga, Paula , Morawska, Lídia , Munjal, Kavita , Murray, Christopher J L , Nagarajan, Ahamarshan Jayaraman , Naik, Ganesh R. , Najdaghi, Soroush , Davani, Delaram Narimani , DELETE-ME, Nawsherwan, Nazri-Panjaki, Athare , Negoi, Ruxandra Irina , Nematollahi, Soroush , Nguyen, Hau Thi Hien, Nguyen, Hau Thi Hien, Nguyen, Phat Tuan , Nguyễn, Văn Thành , Niazi, Robina Khan, Nikoobar, Ali , Sá, Antonio Tolentino Nogueira de , Nomura, Shuhei , Nzoputam, Chimezie Igwegbe , Oancea, Bogdan , Ojo-Akosile, Tolulope R, Oliveira, Gláucia Maria Moraes de , Olorukooba, Abdulhakeem Abayomi , Osuagwu, Uchechukwu Levi , Ouyahia, Amel, A, Mahesh Padukudru P, Panagiotakos, Demosthenes B. , Parikh, Romil R., Park, Seoyeon , Pedersini, Paolo , Peprah, Emmanuel , Perico, Norberto, Petermann-Rocha, Fanny Emily, Plotnikov, Evgenii , Полибин, Р. В. , Postma, Maarten J. , Prasad, Manya , Qian, Gangzhen , Rahmanian, Mohammad , Rajaa, Sathish , Rajput, Prashant , Ramadan, Mahmoud M. , Rane, Amey, Rashidi, Mohammad‐Mahdi , Razo, Christian , Reddy, Murali Mohan Rama Krishna, Remuzzi, Giuseppe, Rezaei, Negar , Rezaeian, Mohsen , Rocha, Hermano Alexandre Lima , Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo , Romoli, Michele, Romozzi, Marina, Roy, Nitai , Saddik, Basema Ahmad, Sahoo, Pragyan Monalisa , Salaroli, Luciane Bresciani , Samuel, Vijaya Paul, Samy, Abdallah M , Santric-Milicevic, Milena M., Saravanan, Aswini, Schlaich, Markus P. , Sethi, Yashendra , Seylani, Allen, Shaaban, Ahmed Nabil , Shafie, Mahan , Shaikh, Summaiya Zareen , Shamsutdinova, Alfiya, Sharifan, Amin , Rad, Javad Sharifi, Sharma, Vishal, Shashamo, Bereket Beyene , Shetty, Premalatha K, Shigematsu, Mika, Shorofi, Seyed Afshin, Singh, Paramdeep , Singh, Puneetpal , Singh, Surjit , Sobia, Farrukh , Solanki, Shipra, Soraneh, Soroush , Spartalis, Michael, Srinivasamurthy, Suresh Kumar , Stanikzai, Muhammad Haroon , Sun, Zhong , Swain, Chandan Kumar , Damavandi, Payam Tabaee , Tabatabaeizadeh, Seyed-Amir, Tabche, Celine , Taiba, Jabeen , Tamuzi, Jacques Lukenze , Tan, Ker‐Kan , Teramoto, Masayuki , Thakur, Ramna, Thankappan, Kavumpurathu Raman , Thayakaran, Rasiah , Thirunavukkarasu, Sathish, Ticoalu, Jansje Henny Vera, Tiwari, Krishna Raj , Tonelli, Marcello , Topór-Mądry, Roman , Tovani-Palone, Marcos Roberto Roberto, Tran, Jasmine, Tran, Thang Huu , Duc, Nguyen Tran Minh , Truelsen, Thomas Clement, Unim, Brigid, Vahdati, Sanaz, Vaithinathan, Asokan Govindaraj , Eynde, Jef Van den , Vladimirov, Sergey Konstantinovitch , Waheed, Yasir, Wahood, Waseem , Walde, Mandaras Tariku, Wang, Yanzhong , Wickramasinghe, Nuwan Darshana , Wolfe, Charles D. A., Wubie, Yihun Miskir, Xiao, Hong , Xu, Xiaoyue , Yano, Yuichiro , Yarahmadi, Amir , Ye, Pengpeng, Yon, Dong Keon , Zanghì, Aurora , Zare, Iman, Zastrozhin, Michael, Zhang, Zhi-Jiang , Zhang, Zhiqiang , Zhang, Zhiqiang, Zhao, Hanqing , Zhou, Shang Cheng, Zhumagaliuly, Abzal , Zia, Hafsa, Roth, Gregory A., Topór‐Mądry, Roman , Oliveira, Arão Belitardo , Rahim, Fakher , Saddik, Basema , Waheed, Yasir , Liu, Xuefeng , Zhang, Yunquan , Ozair, Ahmad , Buendía, Jefferson Antonio , Korja, Miikka , Baig, Atif Amin , Shanawaz, Mohd , Elgendy, Islam Y , Hankey, Graeme J , Alif, Sheikh M , Rezaei, Negar , Bhagavathula, Akshaya Srikanth , Van den Eynde, Jef , Ozair, Ahmad , Collaborators, GBD 2021 Global Subarachnoid Hemorrhage Risk Factors, Rautalin, Ilari Matias , Volovici, Victor , Ranta, Annemarei , Rinkel, Gabriël J.E. , Abate, Yohannes Habtegiorgis, Abbastabar, Hedayat , Abd-Allah, Foad , Abdi, Parsa , Abdollahi, Arash , Abiodun, Olugbenga Olusola , Aboagye, Richard Gyan , Abouzid, Mohamed , Abtahi, Dariush , Abu‐Rumeileh, Samir , Abualhasan, Ahmed , Abu‐Zaid, Ahmed , Addo, Isaac Yeboah , Adedoyin, Rufus Adesoji , Adra, Saryia , Ahinkorah, Bright Opoku , Ahmed, Ali , Ahmed, Haroon , Ahmed, Syed Anees , Aji, Budi , Al‐Ajlouni, Yazan A. , Al‐Aly, Ziyad , ALBashtawy, Mohammed , Aljunid, Syed Mohamed , Alomari, Mahmoud A. , Alrawashdeh, Ahmad , Alsabri, Mohammed A., Salman, Rustam Al‐Shahi , Al‐Tammemi, Ala’a B. , Al‐Worafi, Yaser Mohammed , Aly, Hany Z. , Alzoubi, Karem Hasan , Amani, Reza, Anderlini, Deanna , Anil, Abhishek , Arabloo, Jalal , Ärnlöv, Johan , Arumugam, Ashokan , Aryan, Zahra , Jafarabadi, Mohammad Asghari , Ashraf, Tahira , Athari, Seyyed Shamsadin , Azzam, Ahmed Y , Babu, Giridhara R. , Bako, Abdulaziz Tijjani , Banach, Maciej , Bandyopadhyay, Soham , Banik, Biswajit , Bardhan, Mainak , Barqawi, Hiba Jawdat , Barua, Lingkan , Beyene, Kebede Abera , Bhat, Vivek, Bhatti, Gurjit Kaur , Bhatti, Jasvinder Singh , Bijani, Ali , Bikbov, Boris , Birhanu, Mulugeta Molla , Bitra, Veera Raghavulu , Boloor, Archith , Brenner, Hermann , Bugiardini, Raffaele , Călina, Daniela Cornelia , Campos, Luciana Aparecida , Campos‐Nonato, Ismael , Carvalho, Félix , Castañeda-Orjuela, Carlos A , Catapano, Alberico Luigi , Cegolon, Luca , Chakraborty, Chiranjib , Chakraborty, Sandip , Chandika, Rama Mohan , Chaudhary, Anis Ahmad , Chi, Gerald , Ching, Patrick R , Chopra, Hitesh , Choudhari, Sonali Gajanan , Chowdhury, E. , Chu, Dinh‐Toi , Chung, Sheng‐Chia , Silva, Alanna Gomes da , Dai, Xiaochen , Dalal, Koustuv , D’Amico, Emanuele , Dashti, Mohsen , Davletov, Kairat , Cruz-Góngora, Vanessa Vianey De la , Delgado‐Enciso, Iván , Devanbu, Vinoth Gnana Chellaiyan, Dibas, Mahmoud , Doheim, Mohamed Fahmy , Dongarwar, Deepa , D’Oria, Mario , Doshi, Ojas Prakashbhai , Doshi, Rajkumar , Efendi, Defi , Efendi, Ferry , Elhadi, Muhammed , Eltahir, Mohd. Elmagzoub , Fabin, Natalia , Fagbamigbe, Adeniyi Francis , Fahim, Ayesha , Fares, Jawad , Ferreira, Nuno Bravo , Gandhi, Aravind P. , Garg, Ravindra Kumar , Gebrehiwot, Mesfin , Ghadimi, Delaram J. , Ghahramani, Sulmaz , Ghazy, Ramy Mohamed , Ghozy, Sherief , Gilani, Jaleed Ahmed , Gnedovskaya, Elena V. , Hadei, Mostafa , Hamidi, Samer , Hanifi, Nasrin , Haro, Josep María , Hasan, Faizul , Tabatabaei, Mahgol Sadat Hassan Zadeh , Heidari, Mohammad , Hemmati, Mehdi , Holla, Ramesh , Hostiuc, Sorin , Huang, Junjie , Huynh, Hong-Han , Ikeda, Nayu , Ilaghi, Mehran , Ilesanmi, Olayinka Stephen , Ilić, Irena , Ilić, Milena , Islam, Md. Rabiul , Ismail, Nahlah Elkudssiah , Iso, Hiroyasu , Jafarzadeh, Abdollah , Jairoun, Ammar Abdulrahman , Kalani, Rizwan, Kamal, Vineet Kumar , Kanchan, Tanuj , Karami, Jafar , Karaye, Ibraheem M. , Karimi, Yeganeh , Kesse‐Guyot, Emmanuelle , Khan, Fayaz, Khatatbeh, Haitham , Khatatbeh, Moawiah Mohammad , Kheirallah, Khalid Ahmed , Khidri, Feriha Fatima , Khormali, Moein , Kısa, Adnan , Kısa, Sezer , Kivimäki, Mika , Kolahi, Ali‐Asghar , Kompani, Farzad , Kostev, Karel , Kothari, Nikhil , Kunutsor, Setor K. , Kurniasari, Maria Dyah , Kusuma, Dian Palupi , Kytö, Ville , Vecchia, Carlo La , Lahariya, Chandrakant , Latief, Kamaluddin , Lee, Seung Won , Lee, Wei‐Chen , Leonardi, Matilde, Liu, Xuefeng , Lohner, Valerie , Lorenzovici, László , Lotufo, Paulo A. , Lucchetti, Giancarlo , Lusk, Jay B. , Amin, Hawraz Ibrahim M. , Malhotra, Armaan Kush , Malhotra, Kashish , Malta, Déborah Carvalho , Mansournia, Mohammad Alì , Mantovani, LG , Manu, Emmanuel, Marino, Mirko , Martínez, Ramón , Martini, Santi , Martorell, Miquel , Marzo, Roy Rillera , Mathangasinghe, Yasith , Mathews, Elezebeth , Mehmood, Asim , Mehrabani-Zeinabad, Kamran , Menezes, Ritesh G. , Meo, Sultan A , Meretoja, Atte , Meštrović, Tomislav , Sá, Ana Carolina Micheletti Gomide Nogueira de , Minh, Le Huu Nhat , Mirică, Andreea , Мirrakhimov, Erkin М , Mirza‐Aghazadeh‐Attari, Mohammad , Mishra, Ajay Kumar , Mohamed, Ahmed Ismail , Mohammadi, Soheil , Mohammadian-Hafshejani, Abdollah , Mokdad, Ali H. , Molinaro, Sabrina , Momani, Shaher , Ghalibaf, AmirAli Moodi , Moradi, Maryam , Msherghi, Ahmed A.A. , Ansari, Noureddin Nakhostin , Nargus, Shumaila , Natto, Zuhair S. , Nauman, Javaid , DELETE-ME, Nawsherwan, Nayak, Vinod C , Newton, Charles R. , Nigatu, Yeshambel T. , Noubiap, Jean Jacques , Nugen, Fred , Oduro, Michael Safo , Okati‐Aliabad, Hassan , Okeke, Sylvester Reuben , Okekunle, Akinkunmi Paul , Olagunju, Andrew T , Olaiya, Muideen Tunbosun , Olufadewa, Isaac Iyinoluwa , Ornello, Raffaele , Ortiz‐Prado, Esteban , Ouyahia, Amel , Owolabi, Mayowa , Padrón‐Monedero, Alicia , Padubidri, Jagadish Rao , Panos, Leonidas D , Pantazopoulos, Ioannis N. , Parikh, Romil R., Patel, Jay , Patel, Urvish , Patoulias, Dimitrios , Pereira, Gavin F , Perianayagam, Arokiasamy , Perna, Simone , Petermann‐Rocha, Fanny , Philip, Anil K. , Пирадов, М. А. , Pradhan, Jalandhar , Puvvula, Jagadeesh , Qasim, Nameer Hashim , Raggi, Alberto , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Rahmani, Amir Masoud , Sanati, Ali Rajabpour , Ramasamy, Shakthi Kumaran , Ramazanu, Sheena , Rathish, Devarajan , Rawaf, Salman , Redwan, Elrashdy M , Remuzzi, Giuseppe , Romoli, Michele, Romozzi, Marina , Ross, Allen Guy , Rout, Himanshu Sekhar , Roy, Priyanka , Saad, Aly M A , Saadatian, Zahra , Sabour, Siamak , Sacco, Simona , Sadeghi, Erfan , Saeed, Usman, Sharif‐Askari, Fatemeh Saheb , Sahebkar, Amirhossein , Sajib, Md Refat Uz Zaman , Saleh, Mohamed A. , Samodra, Yoseph Leonardo , MİLİCEVİC, Milena Santric, Saravanan, Aswini , Sarkar, Tanmay, Sarode, Sachin Chakradhar , Sartorius, Benn , Satpathy, Maheswar , Schneider, Ione Jayce Ceola , Schuermans, Art , Selvaraj, Siddharthan , Senthilkumaran, Subramanian , Sepanlou, Sadaf Ghajarieh , Shahwan, Moyad Jamal , Shamim, Muhammad Aaqib , Shamsi, Anas , Shannawaz, Mohammed , Rad, Javad Sharifi, Sharma, Vishal , Shittu, Aminu , Shiue, Ivy , Shlobin, Nathan A. , Siddig, Emmanuel Edwar , Spartalis, Michael , Stanaway, Jeffrey D , Starodubova, Antonina Vladimirovna , Szarpak, Łukasz , Tabatabaeizadeh, Seyed‐Amir , Tabatabaeizadeh, Seyed-Amir, Talaat, Iman Mamdouh , Temsah, Mohamad‐Hani , Thakur, Ramna , Thirunavukkarasu, Sathish, Tiwari, Krishna, Truyen, Thien Tan Tri Tai , Tsai, Daniel Hsiang‐Te , Ullah, Atta , Unnikrishnan, Bhaskaran , Unsworth, Carolyn Anne, Usman, Jibrin Sammani , Valizadeh, Rohollah , Varghese, Joe , Vasankari, Tommi Juhani , Venketasubramanian, Narayanaswamy , Vervoort, Dominique , Villafañe, Jorge Hugo , Vinayak, Manish , Wafa, Hatem A , Walde, Mandaras Tariku, Willeit, Peter , Wolfe, Charles D.A. , Wolfe, Charles D. A., Yamagishi, Kazumasa , Yaribeygi, Habib , Yaya, Sanni , Ye, Pengpeng, Yonemoto, Naohiro , Yu, Chuanhua , Zastrozhin, Michael, Zhang, Chen , Zhang, Zhiqiang, Zielińska, Magdalena , Zyoud, Samer H. , Roth, Gregory A. , Feigin, Valery L. , Kulimbet, Mukhtar , Rahim, Fakher

Mayo Clinic

JAMA Neurology | May 23, 2025 | Volume: 82 | Issue: 8 | Pages: 765

10.1001/jamaneurol.2025.1522 | PMID 40406922 Get It

Importance Nontraumatic subarachnoid hemorrhage (SAH) represents the third most common stroke type with unique etiologies, risk factors, diagnostics, and treatments. Nevertheless, epidemiological studies often cluster SAH with other stroke types leaving its distinct burden estimates obscure. Objective To estimate the worldwide burden of SAH. Design, Setting, and Participants Based on the repeated cross-sectional Global Burden of Disease (GBD) 2021 study, the global burden of SAH in 1990 to 2021 was estimated. Moreover, the SAH burden was compared with other diseases, and its associations with 14 individual risk factors were investigated with available data in the GBD 2021 study. The GBD study included the burden estimates of nontraumatic SAH among all ages in 204 countries and territories between 1990 and 2021. Exposures SAH and 14 modifiable risk factors. Main Outcomes and Measures Absolute numbers and age-standardized rates with 95% uncertainty intervals (UIs) of SAH incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) as well as risk factor–specific population attributable fractions (PAFs). Results In 2021, the global age-standardized SAH incidence was 8.3 (95% UI, 7.3-9.5), prevalence was 92.2 (95% UI, 84.1-100.6), mortality was 4.2 (95% UI, 3.7-4.8), and DALY rate was 125.2 (95% UI, 110.5-142.6) per 100 000 people. The highest burden estimates were found in Latin America, the Caribbean, Oceania, and high-income Asia Pacific. Although the absolute number of SAH cases increased, especially in regions with a low sociodemographic index, all age-standardized burden rates decreased between 1990 and 2021: the incidence by 28.8% (95% UI, 25.7%-31.6%), prevalence by 16.1% (95% UI, 14.8%-17.7%), mortality by 56.1% (95% UI, 40.7%-64.3%), and DALY rate by 54.6% (95% UI, 42.8%-61.9%). Of 300 diseases, SAH ranked as the 36th most common cause of death and 59th most common cause of DALY in the world. Of all worldwide SAH-related DALYs, 71.6% (95% UI, 63.8%-78.6%) were associated with the 14 modeled risk factors of which high systolic blood pressure (population attributable fraction [PAF] = 51.6%; 95% UI, 38.0%-62.6%) and smoking (PAF = 14.4%; 95% UI, 12.4%-16.5%) had the highest attribution. Conclusions and Relevance Although the global age-standardized burden rates of SAH more than halved over the last 3 decades, SAH remained one of the most common cardiovascular and neurological causes of death and disabilities in the world, with increasing absolute case numbers. These findings suggest evidence for the potential health benefits of proactive public health planning and resource allocation toward the prevention of SAH.
Comparative Performance of Scribe and Database Search Engines in Metaproteomic Profiling of a Ground-Truth Microbiome Dataset
Rajczewski, Andrew T. , Mehta, Subina , Wagner, Reid , Gabriel, Wassim , Johnson, James E. , Do, Katherine , Vintila, Simina , Wilhelm, Mathias , Kleiner, Manuel , Searle, Brian C. , Griffin, Timothy J , Jagtap, Pratik D , Searle, Brian C , Griffin, Timothy J. , Jagtap, Pratik

Mayo Clinic

No container title available | May 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.05.15.654320 | PMID 40475569 Get It

ABSTRACT Mass spectrometry-based metaproteomics, the identification and quantification of thousands of proteins expressed by complex microbial communities, has become pivotal for unraveling functional interactions within microbiomes. However, metaproteomics data analysis encounters many challenges, including the search of tandem mass spectra against a protein sequence database using proteomics database search algorithms. We used a ground-truth dataset to assess a spectral library searching method against established database searching approaches. Mass spectrometry data collected by data-dependent acquisition (DDA-MS) was analyzed using database searching approaches (MaxQuant and FragPipe), as well as using Scribe with Prosit predicted spectral libraries. We used FASTA databases that included protein sequences from microbial species present in the ground-truth dataset along with background protein sequences, to estimate error rates and assess the effects on detection, peptide-spectral match quality, and quantification. Using the Scribe search engine resulted in more proteins detected at a 1% false discovery rate (FDR) compared to MaxQuant or FragPipe, while FragPipe detected more peptides verified by PepQuery. Scribe was able to detect more low-abundance proteins in the microbiome dataset and was more accurate in quantifying the microbial community composition. This research provides insights and guidance for metaproteomics researchers aiming to optimize results in their analysis of DDA-MS data.